OTCMKTS:BIOVF Swedish Orphan Biovitrum Q3 2026 Earnings Results & Report $45.72 0.00 (0.00%) As of 10/23/2026 03:56 PM Eastern Swedish Orphan Biovitrum beat analyst earnings expectations in its Q3 2026 results, released October 27, 2026. The company reported EPS of $0.71 versus the $0.62 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 27, 2026TimeBefore Market Opens Swedish Orphan Biovitrum EPS ResultsActual EPS$0.71Consensus EPS $0.62Beat/MissBeat by +$0.09One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersSwedish Orphan Biovitrum Revenue ResultsActual RevenueN/AExpected Revenue$890.89 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Swedish Orphan Biovitrum Q3 2026 Earnings FAQ Did Swedish Orphan Biovitrum beat earnings estimates for Q3 2026? Swedish Orphan Biovitrum (OTCMKTS:BIOVF) reported earnings of $0.71 per share for Q3 2026, beating the consensus estimate of $0.62. The report was announced on Tuesday, October 27, 2026. Swedish Orphan Biovitrum Earnings HeadlinesHarry Gillis Raises Swedish Orphan Biovitrum Price Target to SEK570, Reiterates Buy on Tryngolza-Led Growth UpsideOctober 20, 2026 | tipranks.comSwedish Orphan Biovitrum (BIOVF) Projected to Announce Quarterly Earnings on TuesdayOctober 20, 2026 | americanbankingnews.comWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured to be lining up a Nasdaq debut before Thanksgiving… at a valuation of up to $2 trillion. But here’s what nobody’s talking about… A raise of about $100 billion doesn’t just make headlines. It puts an enormous spotlight on the AI industry. And as investors rush to find the next big opportunity in artificial intelligence, some of the most interesting plays may be hiding outside traditional AI stocks.October 27 at 1:00 AM | Crypto 101 Media (Ad)Sobi Completes Class C Share Issue to Fund Employee Incentive ProgrammeAugust 31, 2026 | tipranks.comSobi partners with Innate Pharma in $580m lacutamab deal to expand rare cancer portfolioAugust 10, 2026 | tipranks.comMitchell Kapoor Reiterates Buy on Swedish Orphan Biovitrum, Maintains SEK575 12-Month Price Target Amid Solid Late-Stage Pipeline and CEO TransitionAugust 3, 2026 | tipranks.comSee More Swedish Orphan Biovitrum Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Swedish Orphan Biovitrum? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Swedish Orphan Biovitrum and other key companies, straight to your email. Email Address About Swedish Orphan BiovitrumSwedish Orphan Biovitrum (OTCMKTS:BIOVF) AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options. Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements. The company also conducts research and development to expand its pipeline of treatments for rare diseases. Headquartered in Stockholm, Sobi serves patients and healthcare providers internationally through its own commercial operations and strategic partnerships. The company traces its roots to Swedish pharmaceutical businesses and adopted the Swedish Orphan Biovitrum name following the combination of Swedish Orphan and Biovitrum in 2010. Its products are marketed across Europe, North America and other international markets, depending on the therapy and regional approvals.View Swedish Orphan Biovitrum ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings T-Mobile US (10/28/2026)Alphabet (10/28/2026)Alphabet (10/28/2026)Carvana (10/28/2026)eBay (10/28/2026)Garmin (10/28/2026)O'Reilly Automotive (10/28/2026)Equinor ASA (10/28/2026)Phillips 66 (10/28/2026)AON (10/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
